At least two in five U.S. adults — more than 57 million people – under the age of 65 with “private insurance could be eligible for GLP-1 drugs,” a new KFF analysis shows. At least two in five U.S. adults — more than 57 million people – under the age of 65 with “private insurance could be eligible for GLP-1 drugs,” a new KFF analysis shows. Healthcare, /healthcare, Innovation, /innovation, Healthcare, /healthcare, Business, /business, Innovation Rx: Technologies, /feature/innovation-rx/technologies, business, pharma, standard
